BFRI Biofrontera Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1858685 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.8%
TTM net income YoY61.6%
TTM EPS YoY76.4%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-14.2%
Net margin-13.8%
FCF margin-17.2%
EBITDA margin-14.0%
Returns
ROE-988.4%
ROA-28.8%
ROIC (approx.)—
Asset turnover2.09x
Leverage & solvency
Liabilities / assets75.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.25x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $41.70M | $37.32M | $34.07M | $28.67M | $24.10M |
| R&D expense | $3.72M | $2.09M | $77,000 | — | — |
| SG&A expense | $37.75M | $33.79M | $18.49M | $35.14M | $36.51M |
| Operating income | -$11.35M | -$17.21M | -$22.68M | -$18.58M | -$25.20M |
| Interest expense | — | — | $220,000 | $12,000 | $344,000 |
| Pretax income | -$10.51M | -$17.74M | -$20.12M | -$608,000 | -$37.66M |
| Income tax | $25,000 | $22,000 | $14,000 | $32,000 | $56,000 |
| Net income | -$10.54M | -$17.76M | -$20.13M | -$640,000 | -$37.71M |
| EBITDA | -$11.21M | -$16.79M | -$22.08M | -$18.48M | -$25.08M |
| EPS (basic) | -1.04 | -3.22 | -13.02 | -0.61 | -4.28 |
| EPS (diluted) | -1.04 | -3.22 | -13.02 | -0.61 | -4.28 |
| Weighted avg. shares (diluted) | 10.17M | 5.52M | 1.55M | 1.06M | 8.81B |
| Banking | |||||
| Net interest income | — | — | -$468,000 | -$195,000 | -$344,000 |
| Balance sheet | |||||
| Cash & equivalents | $6.39M | $5.91M | $1.34M | $17.21M | $24.55M |
| Receivables | $7.29M | — | — | — | — |
| Inventory | $1.43M | $6.65M | $10.91M | $7.17M | $4.46M |
| Current assets | $18.08M | $20.70M | $23.07M | $43.14M | $46.42M |
| PP&E, net | $2.16M | $80,000 | $134,000 | $204,000 | $267,000 |
| Intangibles | $2.65M | $35,000 | $2.63M | $3.03M | $3.45M |
| Total assets | $28.56M | $22.10M | $27.93M | $50.88M | $53.22M |
| Current liabilities | $11.89M | $12.02M | $18.09M | $20.89M | $13.84M |
| Short-term debt | — | — | $3.90M | — | — |
| Total liabilities | $18.08M | $17.67M | $23.14M | $27.01M | $41.88M |
| Shareholders' equity | $10.48M | $4.43M | $4.79M | $23.88M | $11.34M |
| Shares outstanding | 11.65M | 8.87M | 1.52M | 1.33M | 17.10M |
| Cash flow statement | |||||
| Operating cash flow | -$13.36M | -$10.27M | -$24.89M | -$16.20M | -$26.71M |
| Capital expenditure | $2,000 | $10,000 | $5,000 | $38,000 | — |
| Free cash flow | -$13.36M | -$10.28M | -$24.90M | -$16.24M | — |
| Investing cash flow | $3.00M | -$3,000 | $619,000 | -$5.16M | -$11,000 |
| Financing cash flow | $10.85M | $14.84M | $8.41M | $14.02M | $43.19M |
| Depreciation & amortization | $138,000 | $421,000 | $600,000 | $101,000 | $122,000 |
| Stock-based compensation | $951,000 | $1.02M | $1.04M | $1.85M | $129,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.